An FDA Approved Generic Form of Ampyra® (dalfampridine) Is Launched in the U.S.
October 19, 2018
A generic equivalent of Ampyra (dalfampridine), a treatment that is approved to improve walking in adults with MS, has been approved by the U.S. Food and Drug Administration and launched by Mylan NV. Dalfampridine extended-release tables 10 mg are currently available. Details on price have not been provided, but people with MS may qualify for a savings program
Dalfampridine is approved by the FDA to improve walking in people with MS. Possible adverse events include seizures, urinary tract infection, nausea, dizziness, insomnia and upper respiratory tract infection. This approval means that Mylan provided evidence that this generic medication is equivalent to Ampyra.
Selecting a therapy should be done by people with MS in collaboration with their MS doctors, taking into account a variety of factors, including the effectiveness of any therapy they are currently using, and weighing potential risks and benefits, costs and lifestyle factors.
Read the dalfampridine medication guide for patients
View the dalfampridine prescription label
Find out if you qualify for the dalfampridine savings program
Frequently Asked Questions: Generic and Biosimilar - Medications